PREVADDUCT
LIVE

Serial Number

98265442

Owner

Adduct Pharmaceutical, Inc.

Attorney

Emily Harris

Filing Date

Nov 10, 2023

Add to watchlist:

No watchlists yet
View on USPTO

PREVADDUCT Trademark

Serial Number: 98265442

PREVADDUCT is a trademark filed by Adduct Pharmaceutical, Inc. on November 10, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Adduct Pharmaceutical, Inc. (2 trademarks)

2711 South Loop Drive, Suite 4400
Ames, IA 50010

Entity Type: 03

Trademark Details

Filing Date

November 10, 2023

Registration Date

Not Registered

Published for Opposition

July 30, 2024

Goods & Services

Anti-inflammatory preparations; Chemical preparations for pharmaceutical or medical purposes, namely, for oxidative damage, isoketal activity and chronic inflammation; Chemical preparations for pharmaceutical or medical purposes, namely, for diseases resulting from oxidative damage, isoketal activity or inflammation; Dietary and nutritional supplements; Digestives for pharmaceutical purposes; Food supplements, namely, anti-oxidants; Medical preparations for the treatment of oxidative damage, isoketal activity and chronic inflammation; Medicinal preparations for inflammation; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of inflammation; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the prevention of oxidative damage; Pharmaceutical preparations for the prevention of chronic inflammation; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of chronic inflammation; Pharmaceutical preparations for the treatment of oxidative damage; Pharmaceutical preparations for the treatment of isoketal activity diseases and conditions; Pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, and immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating asthma; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for inflammation; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Preparation for the relief of pain

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2026 EXRA
SOU EXTENSION 3 GRANTED
Mar 24, 2026 EX3G
SOU EXTENSION 3 FILED
Mar 24, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 24, 2026 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 24, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 24, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 24, 2026 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 24, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 23, 2025 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 23, 2025 AITU
SOU EXTENSION RECEIVED WITH TEAS PETITION
Oct 21, 2025 TPEX
NOTICE OF REVIVAL - E-MAILED
Oct 21, 2025 NREV
PETITION TO REVIVE-GRANTED
Oct 21, 2025 PETG
TEAS PETITION TO REVIVE RECEIVED
Oct 21, 2025 PROA
SOU EXTENSION 2 FILED
Sep 23, 2025 EXT2
ASSIGNED TO EXAMINER
Apr 9, 2025 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2025 EXRA
SOU EXTENSION 1 GRANTED
Mar 25, 2025 EX1G
SOU EXTENSION 1 FILED
Mar 24, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 24, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 24, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 24, 2024 CNSA
ASSIGNED TO EXAMINER
Jun 18, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 29, 2024 NWOS
NEW APPLICATION ENTERED
Nov 10, 2023 NWAP